Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study
1 other identifier
observational
500
1 country
1
Brief Summary
The population receiving immunotherapy is heterogeneous. Multiple factors, including combination treatment modalities, influence the immune response, and survival outcomes also vary among individuals receiving immunotherapy. The aim of this study is to develop and validate a clinical prediction model that can predict survival outcomes of immunotherapy for malignant tumors, and to assess the calibration and discrimination of this model in a prospective independent cohort.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2026
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 19, 2026
CompletedFirst Posted
Study publicly available on registry
June 24, 2026
CompletedStudy Start
First participant enrolled
June 30, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 15, 2029
June 24, 2026
June 1, 2026
3 years
June 19, 2026
June 19, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
overall survival
2 year
progression-free time
2 year
Eligibility Criteria
Patients aged ≥18 years with histologically or cytologically confirmed malignant tumors and who are planned to receive immune checkpoint inhibitor-based therapy.
You may qualify if:
- Age ≥ 18 years;
- Histologically or cytologically confirmed malignant tumor;
- Planned to receive immune checkpoint inhibitor (e.g., PD-1/PD-L1 inhibitor)-based therapy (monotherapy or in combination with chemotherapy/targeted therapy/radiotherapy, etc.);
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
- Adequate organ function (with reference to laboratory tests such as complete blood count, liver and kidney function tests);
- Voluntary participation in this study, signed informed consent, and willingness to comply with follow-up.
You may not qualify if:
- Active autoimmune disease requiring systemic immunosuppressive therapy (physiological doses of glucocorticoid replacement therapy or inhaled steroids are permitted);
- Active, uncontrolled severe infection, or known human immunodeficiency virus (HIV) infection;
- Pregnant or breastfeeding women;
- Any unstable systemic disease (including but not limited to severe cardiac, hepatic, or renal insufficiency).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
West China Hospital of Sichuan University
Chengdu, 610041, China
MeSH Terms
Conditions
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD. PhD
Study Record Dates
First Submitted
June 19, 2026
First Posted
June 24, 2026
Study Start
June 30, 2026
Primary Completion (Estimated)
June 15, 2029
Study Completion (Estimated)
June 15, 2029
Last Updated
June 24, 2026
Record last verified: 2026-06